CYTOVENE Drug Patent Profile

Which patents cover Cytovene, and what generic alternatives are available?

Cytovene is a drug marketed by Roche Palo and Cheplapharm and is included in two NDAs.

The generic ingredient in CYTOVENE is ganciclovir sodium. There are twenty-seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ganciclovir sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cytovene

A generic version of CYTOVENE was approved as ganciclovir sodium by HIKMA on July 16^th, 2003.

Summary for CYTOVENE

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	150
Clinical Trials:	10
Drug Prices:	Drug price information for CYTOVENE
What excipients (inactive ingredients) are in CYTOVENE?	CYTOVENE excipients list
DailyMed Link:	CYTOVENE at DailyMed

See drug prices for CYTOVENE

Recent Clinical Trials for CYTOVENE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Heart, Lung, and Blood Institute (NHLBI)	Phase 3
Fred Hutchinson Cancer Research Center	Phase 3
Rho Federal Systems Division, Inc.	Phase 1

See all CYTOVENE clinical trials

US Patents and Regulatory Information for CYTOVENE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-001	Dec 22, 1994		DISCN	Yes	No
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-002	Dec 12, 1997		DISCN	Yes	No
Cheplapharm	CYTOVENE	ganciclovir sodium	INJECTABLE;INJECTION	019661-001	Jun 23, 1989		DISCN	Yes	No

Expired US Patents for CYTOVENE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-001	Dec 22, 1994	4,355,032
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-002	Dec 12, 1997	4,423,050
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-001	Dec 22, 1994	4,507,305
Cheplapharm	CYTOVENE	ganciclovir sodium	INJECTABLE;INJECTION	019661-001	Jun 23, 1989	4,355,032
Cheplapharm	CYTOVENE	ganciclovir sodium	INJECTABLE;INJECTION	019661-001	Jun 23, 1989	4,507,305
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-002	Dec 12, 1997	4,507,305
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-002	Dec 12, 1997	4,642,346

EU/EMA Drug Approvals for CYTOVENE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Dr. Gerhard Mann, Chem.-Pharm. Fabrik GmbH..	Vitrasert Implant	ganciclovir	EMEA/H/C/000120The Vitrasert implant is indicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) (See 4.4. Special warnings and special precautions for use).	Withdrawn	no	no	no	1997-03-18

International Patents for CYTOVENE

See the table below for patents covering CYTOVENE around the world.

Country	Patent Number	Title	Estimated Expiration
Ireland	53731	9-(1,3-DIHYDROXY-2-PROPOXYMETHYL) GUANINE AS ANTIVIRAL AGENT
Czechoslovakia	235042	METHOD OF 9-(L1,3- DIHYDROXY-2-PROPOMETHYL ) P-GUANIN PREPARATION
Netherlands	930139
Hong Kong	67088	9-(1,3-DIHYDROXY-2-PROPOXYMETHYL)-GUANINE AS ANTIVIRAL AGENT
Canada	1305139	UTILISATION DE LA 9-(1,3-DIHYDROXY-2-PROPOXYMETHYL)GUANINE COMME AGENT ANTIVIRAL (9-(1,3-DIHYDROXY-2-PROPOXYMETHYL)GUANINE AS ANTIVIRAL AGENT)
Spain	524899
New Zealand	200691	AN ANTIVIRAL GUANINE DERIVATIVE

Supplementary Protection Certificates for CYTOVENE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0694547	C300071	Netherlands		PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920
0694547	03C0003	France		PRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920
0694547	2002/028	Ireland		PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
0694547	SPC/GB02/027	United Kingdom		PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425

Last updated: February 15, 2026

What Are the Market Dynamics for CYTOVENE?

Cytovene (ganciclovir) is an antiviral drug primarily used to treat cytomegalovirus (CMV) infections, especially in immunocompromised patients such as transplant recipients and AIDS patients. The market for Cytovene is influenced by several factors:

Disease Prevalence and Patient Demographics

The demand for Cytovene correlates with the incidence of CMV infections. CMV affects an estimated 60-100% of the adult population worldwide by age 60, with higher prevalence in immunocompromised individuals.[1] The increasing number of organ transplants, solid organ transplant recipients, and HIV/AIDS cases drives higher demand.

Competition and Alternatives

Valganciclovir (Valcyte) is an oral prodrug of ganciclovir offering easier administration. Its market share is expanding due to convenience, impacting Cytovene sales. Additionally, newer agents like letermovir are emerging for CMV prophylaxis, mainly in transplant settings.

Regulatory and Patent Status

Cytovene was first approved in the 1980s. As of 2023, its patents have expired, allowing generic manufacturers to enter the market. This has driven prices down and increased accessibility but has compressed profit margins for brand manufacturers.

Market Penetration and Usage

Initial usage focused on intravenous formulations in hospital settings. The shift toward outpatient management via oral formulations like valganciclovir has limited Cytovene's use to specialized cases and hospitalized patients.

Geographical Variations

North America and Europe dominate the market due to advanced healthcare infrastructure and transplant volumes. Emerging markets show increasing demand as healthcare systems expand and transplant procedures rise.

What Is the Financial Trajectory of CYTOVENE?

Revenue Trends

Post-patent expiry, Cytovene's revenue declined sharply in major markets:

Year	Estimated Global Revenue (USD Millions)	Change from Previous Year
2020	200	-10%
2021	150	-25%
2022	120	-20%

The decline reflects increased generic competition, reduced hospital use, and a shift to oral alternatives.

Cost Structure and Pricing

Original branded Cytovene priced at approximately $1,000 per vial in the US. Generics now price around $200 per vial, reducing profitability.

Market Drivers

• Growing transplant procedures: Approximately 50,000 kidney transplants annually in the US as of 2022, with CMV prophylaxis requiring antiviral therapy.[2]
• Advancements in HIV management: Better antiretroviral therapies have increased the lifespan of HIV+ patients, prolonging CMV risk.

Pipeline and Future Outlook

There are no new formulations or major reformulations of Cytovene in late-stage development. The current market faces further erosion as newer therapies take larger market shares.

Investment Implications

Companies vested in Cytovene and its generics face declining revenues. Potential growth could derive from niche applications, such as resistant CMV strains, if supported by clinical trials and regulatory approval.

Key Market Challenges

• Patent expirations lead to price erosion.
• Competition from oral prodrugs reduces hospital-based utilization.
• Emerging treatments (e.g., letermovir) divert prophylaxis market share.
• Variability in global healthcare spending affects access and demand.

What Are the Regulatory and Patent Considerations?

Cytovene’s patent protections expired in the early 2000s. Patents on formulations and uses may still be active in some jurisdictions, but generic manufacturing dominates the landscape. Regulatory pathways for biosimilars are not applicable, as Cytovene is a small molecule.

How Does the Market Compare to Other Antivirals?

Drug	Mode of Action	Administration	Market Share (2023)	Price, USD (approx.)
Ganciclovir (Cytovene)	DNA polymerase inhibitor	IV	Declining	$200/vial (generic)
Valganciclovir	Prodrug of ganciclovir	Oral	Growing	$60/tablet
Letermovir	CMV terminase inhibitor	Oral/IV	Niche, emerging	$250/tablet

Key Takeaways

• Cytovene's market has declined significantly post-patent expiry due to generics and competition from oral alternatives.
• The global demand continues driven by organ transplants and immunosuppressed populations.
• Revenue prospects for Cytovene are limited, with growth potential confined to niche indications or resistant strains.
• Price erosion and competition are shaping a challenging financial environment.
• Future opportunities are tied to clinical developments rather than existing formulations.

---

FAQs

1. Will Cytovene regain market share?
Unlikely, as oral alternatives and newer therapies dominate the treatment landscape, especially outside hospital settings.

2. What factors could sustain Cytovene’s profitability?
Limited niche uses such as treatment-resistant CMV infections may provide some opportunities, contingent on clinical validation.

3. How significant is the impact of generic drugs on Cytovene’s sales?
Generic entry caused a rapid decline in revenue, with prices falling by approximately 80% from peak branded levels.

4. Are there ongoing clinical trials involving Cytovene?
Current research focuses on new antiviral agents; no major trials for Cytovene are in late stages, indicating limited near-term pipeline activity.

5. What alternative therapies are emerging for CMV management?
Drugs like letermovir, maribavir, and brincidofovir are in development or approved for specific indications, challenging Cytovene’s traditional market.

---

References

[1] Centers for Disease Control and Prevention. “CMV Infection Surveillance,” 2022.

[2] American Society of Transplantation. “Transplant Statistics,” 2022.